Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Abstract

PURPOSE:

Non-inflamed (cold) tumors such as leiomyosarcoma do not benefit from immune checkpoint blockade (ICB) monotherapy. Combining ICB with angiogenesis or PARP inhibitors may increase tumor immunogenicity by altering the immune cell composition of the tumor microenvironment (TME). The DAPPER phase II study evaluated the safety, immunologic, and clinical activity of ICB-based combinations in pretreated patients with leiomyosarcoma.

PATIENTS AND METHODS:

Patients were randomized to receive durvalumab 1,500 mg IV every 4 weeks with either olaparib 300 mg twice a day orally (Arm A) or cediranib 20 mg every day orally 5 days/week (Arm B) until unacceptable toxicity or disease progression. Paired tumor biopsies, serial radiologic assessments and stool collections were performed. Primary endpoints were safety and immune cell changes in the TME. Objective responses and survival were correlated with transcriptomic, radiomic, and microbiome parameters.

RESULTS:

Among 30 heavily pretreated patients (15 on each arm), grade ≥ 3 toxicity occurred in 3 (20%) and 2 (13%) on Arms A and B, respectively. On Arm A, 1 patient achieved partial response (PR) with increase in CD8 T cells and macrophages in the TME during treatment, while 4 had stable disease (SD) ≥ 6 months. No patients on Arm B achieved PR or SD ≥ 6 months. Transcriptome analysis showed that baseline M1-macrophage and B-cell activity were associated with overall survival.

CONCLUSIONS:

Durvalumab plus olaparib increased immune cell infiltration of TME with clinical benefit in some patients with leiomyosarcoma. Baseline M1-macrophage and B-cell activity may identify patients with leiomyosarcoma with favorable outcomes on immunotherapy and should be further evaluated.

• Authors: Abdulazeez Salawu, Ben X Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K Berman, Thomas D Pfister, Alberto Hernando-Calvo, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A Gupta, Olubukola Ayodele, Bernard Lam, Aaron R Hansen, Anna Spreafico, Philippe L Bedard, Marcus O Butler, Lisa Avery, Bryan Coburn, Benjamin Haibe-Kains, Lillian L Siu, Albiruni R Abdul Razak
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 29 Issue 20 Pg. 4128-4138 (Oct 13 2023) ISSN: 1557-3265 [Electronic] United States
• PMID: 37566240 (Publication Type: Journal Article)
• Copyright: ©2023 American Association for Cancer Research.